What is Accelagen?
Accelagen operates at the intersection of biotechnology and protein science, specializing in the development and production of high-quality protein reagents. The company offers comprehensive recombinant protein expression and custom protein purification services, crucial for clients engaged in drug discovery and structural biology. Leveraging advanced expression systems including Baculovirus, E. coli, and mammalian platforms, Accelagen is committed to delivering superior protein quality and efficient project timelines. Their expertise extends to the production of critical biomolecules such as antibodies, GPCRs, and therapeutic proteins, positioning them as a vital partner for research and development initiatives.
How much funding has Accelagen raised?
Accelagen has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for Accelagen?
With substantial late-stage funding, Accelagen is poised for significant expansion and scaling of its operations. The recent strategic investment will likely fuel advancements in their proprietary technologies, enhance their service offerings, and potentially broaden their market reach within the global drug discovery and structural biology sectors. This capital infusion is expected to accelerate their mission of providing cost-effective, technically excellent protein solutions, further solidifying their position as a leader in the Gene-to-Protein space.
See full Accelagen company page
